A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED)

A 6-Month, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Alendronate 280-mg Oral Buffered Solution Once Weekly in Patients With Paget's Disease of Bone

To test the safety, effectiveness of MK0217 when taken once a week for six months in treating patients with Paget's bone disease.

Inclusion Criteria:

• Male or female, ages 18 to 90 years with a diagnosis of Paget's bone disease

Exclusion Criteria:

• Patient cannot stand or sit upright for at least 30 minutes
• Patient has difficulty swallowing or problems with digestive system